2.06%| Prev Close: | 0.60 |
|---|---|
| Open: | 0.60 |
| Bid: | 0.58 |
| Ask: | 0.62 |
| 1y Target Est: | N/A |
| Beta: | N/A |
| Next Earnings Date: | N/A |
| Day's Range: | 0.60 - 0.62 |
|---|---|
| 52wk Range: | 0.53 - 0.95 |
| Volume: | 15,250 |
| Avg Vol (3m): | 20,699 |
| Market Cap: | N/A |
| P/E (ttm): | N/A |
| EPS (ttm): | N/A |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- GI Dynamics, Inc. Reports on Progress of the ENDO Trialat Reuters(Fri 26 Apr)
- Change of Directors Interest Noticeat Reuters(Tue 19 Mar)
- EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asiaat Reuters(Tue 19 Mar)
- GI Dynamics Announces Agreement with CMS Medical for Distribution of EndoBarrier® Therapy in BrazilBusiness Wire(Wed 6 Mar)
- CMS Medical to Distribute EndoBarrier Therapy in Brazilat Reuters(Wed 6 Mar)
- GI Dynamics, Inc Q4 and Full-Year 2012 Financial Results Call scheduled for 4:30 pm ET todayCCBN(Tue 5 Mar)
- GI Dynamics Announces Commercial Availability of EndoBarrier® Therapy in Israel for the Treatment of Type 2 Diabetes and/or ObesityBusiness Wire(Wed 27 Feb)
- GI Dynamics to Present at the Cowen Healthcare Conferenceat Reuters(Wed 27 Feb)
- Briefing Call and Webcast on Financial Results for 2012at Reuters(Wed 20 Feb)
- Release of Securities from Voluntary Escrowat Reuters(Tue 19 Feb)
Press Releases
- GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical OfficerBusiness Wire(Wed 1 May)
- GI Dynamics, Inc. Initiates U.S. Pivotal Clinical Trial of EndoBarrier®at Reuters(Tue 15 Jan)
- GI Dynamics Announces Resolution of Litigation with Goreat Reuters(Thu 10 Jan)